Safety and Monitoring of the Treatment with Disease-Modifying Therapies (DMTs) for Multiple Sclerosis (MS).

Vasileios-Periklis Stamatellos,Georgios Papazisis

Current reviews in clinical and experimental pharmacology（2023）

引用 2|浏览5

暂无评分

摘要

Data for oral (Sphingosine 1-phosphate (S1P) receptor modulators, Fumarates, Teriflunomide, Cladribine), injectables (Interferons, Glatiramer acetate, Ofatumumab), and infusion therapies (Natalizumab, Ocrelizumab, Alemtuzumab) are presented.

查看译文

关键词

DMAMS,DMT,Disease-modifying treatments,adverse events,monitoring,multiple sclerosis,safety

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要